Delivery Order SPE2DB24D3013-SPE2DB25FFQWB
- Not listed
- The Defense Logistics Agency awarded a $3,372.82 delivery order to AmerisourceBergen Drug Corp for Qulipta 60 mg tablets (30-count units) on July 22, 2025, with completion scheduled for July 23, 2025. This firm fixed price contract represents a non-competitive set-aside delivery order under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical. The pharmaceutical product will be performed at the vendor's corporate office location in Conshohocken,...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,373.74 to AmerisourceBergen Drug Corp for the supply of Qulipta 60 mg tablets (30-count package) on July 18, 2025, with an ultimate completion date of July 21, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and is being performed at the contractor's location in Conshohocken, Pennsylvania. The award represents a routine pharmaceutical supply transaction under the DLA's...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,154.79 to AmerisourceBergen Drug Corp for the supply of Qulipta 60 mg tablets (30-count) on September 17, 2025, with an ultimate completion date of September 18, 2025. This competitive, non-set-aside contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999.99 million through...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Qulipta 60 mg tablets (30-count packages) under a firm fixed-price contract valued at $1,649.05. The award, issued on August 8, 2025, with an ultimate completion date of August 11, 2025, represents a non-competitive delivery order without set-aside designation. AmerisourceBergen will perform this contract from its corporate office in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a $2,309.58 delivery order to AmerisourceBergen Drug Corp for Qulipta 60 mg tablets (30-count units) on May 12, 2025, with an ultimate completion date of May 13, 2025. This firm fixed-price delivery order represents a competitive award with no set-aside designation and is performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal medical procurement vendor,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Qulipta 60 mg tablets (30-count packages) under a firm fixed-price contract. The order, valued at $2,400.59, represents a competitive award with no set-aside designation and a completion deadline of July 28, 2025. AmerisourceBergen will fulfill this order from its corporate office location in Conshohocken, Pennsylvania, where the company maintains its headquarters as a major...
- The Defense Logistics Agency awarded a delivery order valued at $6,036.88 to AmerisourceBergen Drug Corp for the supply of Qulipta 60 mg tablets (30-count units) on September 17, 2025, with completion scheduled for September 18, 2025. This firm fixed-price delivery order represents a non-competitive award under the company's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The pharmaceutical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Qulipta 60 mg tablets (30-count packages) with a contract ceiling value of $5,993.70. This is a firm fixed-price delivery order with no set-aside designation, reflecting a competitive award to the pharmaceutical distributor. The ultimate completion date is set for July 23, 2025, and the product will be delivered to AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $4,755.64 to AmerisourceBergen Drug Corp for the supply of Qulipta 60 mg tablets (30-count) on August 29, 2025, with an ultimate completion date of September 2, 2025. This firm fixed-price delivery order represents a non-set-aside competitive award and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions...
- The Defense Logistics Agency awarded a $2,547.07 delivery order to AmerisourceBergen Drug Corp for Qulipta 60 mg tablets (30-count units) on July 28, 2025, with completion scheduled for July 29, 2025. This firm fixed price contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. The award was competitively awarded with no set-aside designation and will be...
- SPE2DB24D3013Indefinite Delivery Contract
- SPE2DB24D3013-SPE2DB25FFQWBDelivery Order
The Defense Logistics Agency awarded a $1,978.37 firm fixed price delivery order to AmerisourceBergen Drug Corp for 30-count tablets of Qulipta 60 mg, a pharmaceutical product used in neurological treatment. This non-set-aside competitive award was issued on September 23, 2025, with an ultimate completion date of September 24, 2025. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00 and extends through December 2026. The parent IDC serves as a comprehensive global pharmaceutical support vehicle enabling AmerisourceBergen to supply a wide range of brand-name and generic medications, vaccines, and medical supplies to support military healthcare programs worldwide. As a major pharmaceutical distributor and critical federal medical procurement vendor, AmerisourceBergen has demonstrated the capability to meet DLA requirements through open competition across multiple therapeutic domains and delivery scenarios.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.0k | 9/23/25 |